REAL-WORLD EVIDENCE SUPPORTS AN 8-WEEK REGIMEN OF MAVYRET14
*Cure = sustained virologic response (SVR12); HCV RNA < LLOQ 12 weeks after the end of treatment.
†PRS-experienced = prior treatment experience with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir, but no prior treatment experience with an NS5A inhibitor or HCV NS3/4A protease inhibitor.
Real-world data are observable in nature, may be prospectively or retrospectively collected, and are not based on controlled clinical studies. Results from these cohorts may differ from those observed in clinical practice and are not presented in the MAVYRET prescribing information.
This TRIO Health Network study electronically collected data from providers and specialty pharmacies partners between August 2017 and April 2018. Of the 560 in the Total Population, the mean age was 52; 54% were male, 30% were white race, 58% were other or unspecified race, 11% F3 liver fibrosis (as reported by the physician), and 20% had an HCV RNA level >6MM IU/mL. Primary endpoint: PP sustained virologic response at 12 weeks post treatment (SVR12).
The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval.